东阳光药AI制药新突破：推出PROTAC机制AI智能研发平台

Group 1 - The core viewpoint of the articles highlights the launch of the PROTAC mechanism AI intelligent research and development platform by Dongyangguang Pharmaceutical, aimed at accelerating the rational design and clinical transformation of PROTAC lead compounds [1] - Dongyangguang's first AI-driven small molecule innovative drug, HEC169584, has entered the clinical stage, indicating progress in AI pharmaceutical development [1] - According to Grand View Research, the annual compound growth rate of AI in pharmaceuticals could reach as high as 38.8% over the next decade, reflecting significant market potential [1] Group 2 - To address the gap between AI technology companies and traditional pharmaceutical firms, some companies are shifting towards "self-built large models" and "data closed-loop" approaches, exemplified by Dongyangguang's establishment of a proprietary model based on over 20 years of laboratory data [2] - Dongyangguang has developed four core models for drug discovery, including molecular screening and generation, and has launched the HEC-PharmAI model, which includes a knowledge base of over 210,000 formulation recipes and thousands of literature and patents [2] - Mainstream pharmaceutical companies are adopting a "dual-track" strategy, focusing on immediate effects by utilizing AI in ongoing research projects to reduce costs and improve efficiency, while also investing in foundational assets for long-term goals [2]